Effects of technology-based physical activity interventions for women after bariatric surgery: study protocol for a three-arm randomised controlled trial


ABSTRACT
Introduction A recent meta-analysis provided proof of efficacy for mobile technology to increase physical activity or weight loss in the short term. Videoconferencing may also be effective, especially as it reduces the barriers related to face-to-face physical activity interventions. Both technologies seem particularly interesting for bariatric surgery management, but their long-term effects on physical activity maintenance are unknown. Moreover, the mechanisms underlying their effectiveness, such as technology acceptability and motivational processes, have not been examined. The objectives of this study are to determine the effects of two technology-based (mobile technology and videoconferencing) physical activity programmes after bariatric surgery compared with standard care and to assess the contribution of acceptability and motivational mechanisms in explaining these effects on physical activity, physiological measures and health indicators.
Methods and analysis One hundred and twenty young women who have undergone bariatric surgery in the last 3–6 months will be included. The volunteers will be randomly assigned to one of three arms: CONTROL (standard care), ACTI-MOBIL (mobile technology) or ACTI-VISIO (videoconferencing). The primary outcome is the distance travelled during a 6 min walk test relativised according to Capadaglio’s theoretical distance. Secondary outcomes are behavioural measures of physical activity, physiological measures, health indicators, technology acceptability and motivational concepts. Data will be collected at baseline (T0), 3 months (T3) and 6 months (T6). The technology groups will receive a physical activity programme for 12 weeks (between T0 and T3). A mixed model approach will be used to analyse the change in outcomes over time for each group.
Ethics and dissemination This study protocol was reviewed and approved by the French East 1 Protection of Persons Ethics Committee (number: 2020.A00172-37) and the French National Commission for Information Technology and Civil Liberties (number: UCA-R20-034). The results will be disseminated through conference presentations and peer-reviewed publications.
Trial registration number NCT04478331.

INTRODUCTION
Background
Bariatric surgery (BS) is currently the most effective treatment for severe obesity. However, BS alone is insufficient to maintain weight loss and must be combined with physical activity (PA) lifestyle interventions. Women are more concerned than men by physical inactivity and sedentary behaviours, both in the general population and in obesity. Therefore, promotion of PA is essential in the obesity management among women. Despite a multidisciplinary approach, long-term monitoring of BS recipients is poor, and this can lead to health complications. One year after BS, between 10% and 40% of patients are lost to follow-up, and young age is a main predictor of poor 5-year follow-up. PA is the area with the lowest compliance rate, and new strategies that improve PA maintenance might help to sustain monitoring. Technology-based PA promotion programmes have been shown to be relevant for this aim, and several technologies for
use in vulnerable populations have been investigated in recent years. Among them, active video games, virtual reality, connected devices, mobile applications, internet-based and social media and videoconferencing have shown to increase the PA level in the short term, but the medium-term and long-term effects of these technologies are not well known. These technologies may be relevant for promoting post-BS PA but low-cost and widely used technologies such as smartphones should be preferred. To classify potentially useful technologies, the Coventry, Aberdeen & London—Refined’ taxonomy could be used to group them according to the behavioural change techniques they incorporate.

According to this taxonomy, mobile applications, internet-based platforms and devices like activity bracelets activate the main behavioural strategies like goal-setting, self-monitoring and personal feedback. Recent meta-analyses have provided proof of efficacy for mobile technology compared with control condition or offline interventions to increase PA or decrease weight in the short term, but the long-term effects have been insufficiently studied. Another review identified self-monitoring, feedback, goal setting and shaping knowledge as key components of effective eHealth interventions for weight loss maintenance. Based on these data, we assume that mobile technology will have long-term positive effects on PA in patients with BS.

Furthermore, videoconferencing for PA includes monitoring by a professional, social support, teaching motivational strategies, use of communication skills and goal setting. These features are part of both videoconferencing and face-to-face PA interventions, which may explain the lack of outcome differences between these two types of interaction. Videoconferencing seems to be effective after BS, especially as it reduces some of the barriers of face-to-face PA interventions (eg, travel time, distance of offers). Despite a limited sample size, videoconferencing proved to be effective in improving the physical fitness of women waiting for BS.

Mobile technology and videoconferencing are not based on the same behavioural strategies. Mobile applications incorporate strategies with technological regulations (eg, self-monitoring, feedback, goal setting and shaping knowledge), while videoconferencing incorporates strategies with human regulations from both professional and other participants (eg, social support, motivation strategies, communication skills and goal setting). The use of mobile applications is completely autonomous, while videoconferencing is regulated by predetermined meetings. Both types of technology seem promising in BS, but their long-term effects on PA maintenance are unknown.

In addition, the mechanisms underlying the adoption or rejection of technologies in healthcare remain insufficiently studied. Indeed, acceptability is often reduced to a measure of satisfaction, which does not take into account the mechanisms underlying the adoption or rejection of a given technology. For this purpose, it is necessary to use models like the Unified Theory of Acceptance and Use of Technology, which is the most comprehensive and parsimonious model to measure acceptability in the early stages of use. As some technologies are better accepted than others, we can assume that the effects of these technologies may be mediated by their acceptability.

Furthermore, the effectiveness of PA interventions can be explained by motivation processes. The role of motivational constructs in PA behaviour in the field of obesity has been studied through self-determination theory. Self-determination theory is a macrotheory that notably highlights the types of motivation (ie, intrinsic, extrinsic, amotivation) along a continuum. The needs that individuals attempt to satisfy (ie, autonomy, competence, relatedness) and the individual differences in motivation orientation (ie, autonomy, control, impersonal). A systematic review of obesity studies showed that higher autonomous motivation, self-efficacy and self-regulation skills are predictors of increased PA. Moreover, the use of motivational strategies can lead individuals to practice PA regularly and build habits. To become a habit, a positive behaviour must be integrated into the natural environment, disrupting old environmental cues and establishing new ones. The changes associated with BS make this period ideal for the creation of new habits.

The technologies we have selected (mobile technology and videoconferencing) are not based on the same behavioural strategies, but both have the potential to lead to habit development, and we assume that they will be more suitable depending on motivational characteristics. Few randomised control trials have measured motivational concepts, and yet doing so might explain why some technologies are more effective for some people than for others.

The study aims

This study aims to investigate (1) the effects of two technology-based PA programmes (mobile technology and videoconferencing) after BS compared with standard care and (2) the contribution of acceptability and motivational mechanisms in explaining these effects. The main objective is to evaluate the effects of the two technology-based PA programmes on the walking capacity of young women after BS. We expect that the technology groups (ACTI-MOBIL and ACTI-VISIO) will report a higher level of walking capacity at the end of the interventions (T3) compared with the control group, and that this effect will be sustained 3 months later (T6). We do not hypothesise the superiority of one technology over the other, because to our knowledge, no study has yet compared them after BS.

The secondary objectives are (1) to evaluate the effects on behavioural measures of PA, physiological measures and health indicators in the technology groups compared with the control group and (2) to explore the role of acceptability and motivational mechanisms in explaining these effects. We expect that participants in the technology groups (ACTI-MOBIL and ACTI-VISIO) compared with
Participants
To be eligible for the study, individuals must be women between 18 and 40 years old and have undergone BS 3–6 months earlier at a tertiary referral centre for BS (Nice University Hospital, France) with respect to the national recommendations.40 Participants will not be included if they have a smartphone incompatible with the proposed technologies. They will be excluded from the study in cases of serious adverse events, withdrawal of informed consent or violation of the protocol. A serious adverse event reporting form, validated for research and a classification of serious and nonserious adverse events will be made available to those involved in the research protocol to assist them in managing adverse events (for more details on the management of adverse events, see online supplemental additional file 1). Participants may participate in another research protocol if it does not involve new technologies and does not impact PA levels or fitness measurement.

Patient and public involvement
Patients were not involved in the development of the research question, the design, the recruitment or the conduct of the study. Results will be reported individually through a personal report of their measurements and a summary of the overall research findings on request to the principal investigator. For this study, the burden will not be directly assessed by patients. However, measurements will be performed during routine care or according to patient availability.

Recruitment and randomisation
Participants will be recruited by the clinicians at the Nice University Hospital in the south of France. Clinicians will give a general explanation of the study to potentially eligible patients, along with written information, and the participants can ask any questions before signing a written informed consent form (online supplemental additional file 2). Individuals will then undergo all baseline measurements, supplemented by information on their professional occupation, education level, marital status and a description of their PA in the last 5 years. They will then be assigned by the last author to one of the three arms using MinimPy software in a 1:1:1 ratio. The minimisation randomisation method will be used to avoid any imbalance between the three groups. We will stratify on age (≤30 years; >30 years) and the type of BS (sleeve gastrectomy, gastric bypass, other). After randomisation, participants will receive a second written information form with details on their allocation group and will be invited to sign a second informed consent form (online supplemental additional file 2). This procedure of two times consent will be used to avoid deceiving the participants about their allocation and preserve the validity and blinded aspect of the trial.43 Recruitment began on 19 November 2020.

Outcome measurements
Table 1 provides a summary of the measures to be collected. Outcomes will be assessed at baseline (T0), 3

METHODS AND ANALYSIS
Design
Participants will be randomly assigned to one of three groups: an eHealth platform associated with the Fitbit Inspire activity bracelet (ACTI-MOBIL group), a PA programme delivered via videoconferencing (ACTI-VISIO group) or standard care (control group) (figure 1). Outcomes will be assessed at baseline (T0), 3 months (T3) and 6 months later (T6). The technology groups will receive a PA programme for 12 weeks (between T0 and T3). Each participant will be included for a period of 6 months, on average 3–6 months after the BS. Approximately 8 months of recruitment will be required to reach the target sample size. Thus, the total expected duration of the study is 14 months.

the control group will show an improvement on the PA behavioural measures, an improvement on physiological measures and better health indicators. We also expect that these effects will be sustained 3 months later (T6). Technology acceptability based on theoretical models is not usually measured in randomised control trials, and acceptability as assessed by the Unified Theory of Acceptance and Use of Technology 2 model has never been measured for technology-based PA interventions in the context of BS. In addition, few randomised control trials have measured motivational concepts. We assume that technology acceptability and motivational concepts may mediate the effects of technology-based interventions on PA behavioural measures, physiological measures or health indicators.

Figure 1 Flow diagram of study protocol.
months (T3) and 6 months later (T6) in conjunction with routine care in these same follow-up periods. An outpatient visit will be scheduled to perform physical assessments with a professional unaware of the allocation and hypotheses of the study. Self-report questionnaires will be completed directly by the participants online using LimeSurvey CE, V.2.06+ or with paper-and-pencil. A reminder will be made by phone to schedule another visit in case of absence.

**Primary outcome**

The primary outcome is walking capacity assessed by distance travelled during a 6 min walk test (6MWT) associated with measures of energy expenditure (eg, heart rate, oxygen uptake) described in the secondary outcomes. The 6MWT, highly reproducible in obesity, will be performed according to guidelines. Due to weight loss during BS follow-up regardless of PA, the distance travelled in 6MWT increases after BS. Therefore, we will use Capodaglio’s formula including age, sex and body mass index to relativise the walking distance.

**Secondary outcomes**

**Behavioural measures**

**Physical activity level**

Global physical activity questionnaire

7 days AX3 physical activity monitoring

**Stage of change**

Stage of change

**Physiological measures**

**Energetic expenditure**

Oxygen uptake, minute ventilation, carbon dioxide output, respiratory exchange ratio, heart rate measured using Cosmed K5 system

**Muscle strength**

Maximal isometric knee extensor muscles strength (Newton) measured with MicroFET2

**Health indicators**

**Quality of life**

EuroQoL-5-Dimensions and EuroQoL-visual analogue scale

**Body mass index**

Height

**Body composition**

Muscle mass, fat mass, bone mineral content and their theoretical gap with reference values measured with Biody Xpert

**Other measures**

**Technology acceptability**

eHealth acceptability scale

**Programme compliance**

Rate of participation and rate of perceived exertion

**Motivation for PA**

Motivation scale for health-oriented physical activity

**General causality orientation for PA**

General causality orientation scale

**Basic psychological needs**

Basic psychological needs

PA, physical activity.

**Table 1** Summary of measures to be collected

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Instrument</th>
<th>Time of measurement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome</td>
<td>Walking capacity</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td>Physical activity level</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td></td>
<td>Stage of change</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td>Physiological measures</td>
<td>Energetic expenditure</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td></td>
<td>Muscle strength</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td>Health indicators</td>
<td>Quality of life</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td></td>
<td>Body mass index</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td></td>
<td>Body composition</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td>Other measures</td>
<td>Technology acceptability</td>
<td>T0, T3 and T6 except for control group</td>
</tr>
<tr>
<td></td>
<td>Programme compliance</td>
<td>T3 except for control group</td>
</tr>
<tr>
<td></td>
<td>Motivation for PA</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td></td>
<td>General causality orientation for PA</td>
<td>T0, T3 and T6</td>
</tr>
<tr>
<td></td>
<td>Basic psychological needs</td>
<td>T0, T3 and T6</td>
</tr>
</tbody>
</table>

Secondary outcomes

**Behavioural measures of PA**

PA level. PA will be measured using the Global PA Questionnaire validated in the French language. This scale comprises 16 items to assess the frequency and duration of PA during work, transportation, leisure time and time spent sitting in a typical week. The items are used to calculate the energy expenditure score in metabolic equivalent tasks (METs), where 150 min/week of moderate to vigorous PA corresponds to 600 MET-min/week. This self-reported measure will be complemented by an objective evaluation using the Axivity AX3 triaxial accelerometer (AX3, Axivity, Newcastle, UK) worn on the wrist. The sensor will be set to begin recording at midnight the day after the appointment over a 7-day period at 100 Hz with a dynamic range of ±8 g. The AX3 data will be downloaded, resampled, calibrated and analysed using open-source AX3 OmGui software (OmGui V.1.0.0.43, Open Movement, Newcastle University, UK). The AX3 sensor and its wrist location were chosen for their ease of use.
Energetic expenditure. Oxygen uptake, minute ventilation, carbon dioxide output, respiratory exchange ratio and heart rate will be measured during the 6WMT. These parameters will be measured using the Cosmed K5 system (Cosmed K5, Rome, Italy), which consists of a mask and a portable unit. This equipment was chosen for its validity and reproducibility.54

Muscle strength. The maximal isometric knee extensor muscle strength of the left and right lower limbs will be measured with the MicroFET2 (Hoggan Scientific, LLC, Salt Lake City, Utah). Women will be seated in a chair with the assessed limb placed at a knee angle of 90°. They will be asked to push as hard as possible for 5 s against the dynamometer held by a strap attached to the chair. The highest value in Newton (N) of three measurements will be recorded, and the average of both limb results will be used for analysis. A similar measurement protocol has already been used in an obesity study.55

Health indicators

Quality of life. Quality of life will be assessed with the French version of the EuroQol-5-dimensions and a EuroQol-visual analogue scale.56 The EuroQol-5-dimensions comprises five items measuring quality of life along five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. For each dimension, participants have five response options ranging from ‘no problems’ to ‘unable’. The EuroQol-visual analogue scale has a single item for which the women will be asked to rate their current health on a scale from 0: ‘worst imaginable’ to 100: ‘best imaginable’. This generic scale, which has previously been used in a BS study,57 was chosen to ensure consistency in the measurement of quality of life throughout weight loss.

Body mass index. Height (m) and body mass (kg) will be measured and used to calculate the body mass index (kg/m²).

Body composition. Body composition will be measured by bioimpedance using the Bodily Xpert (Aminogram, France): muscle mass (kg), fat mass (kg) and bone mineral content (kg). For the analyses, these measures will be converted to percentages. In addition, the theoretical gap with the reference values (derivative variables based on age, sex, weight and height provided by the French company, Aminogram) will be measured to obtain estimations for muscle mass (kg), fat mass (kg) and bone mineral content (kg).

Other measures

Technology acceptability. The acceptability of technologies (ACTI-MOBIL and ACTI-VISIO groups) will be assessed by the French eHealth acceptability scale,58 including 25 items divided into eight subscales: performance expectancy, effort expectancy, social influence, facilitating conditions, hedonic motivation, price value, habit and behavioural intention. Women will rate each item on a 7-point scale ranging from 1 ‘strongly disagree’ to 7 ‘strongly agree’. This measure will not be assessed in the control group to avoid bias by giving individuals the idea of using a technology, disappointing participants without technology or potentially removing blinding to the group assignment.

Programme compliance. To measure technology-based programme compliance, companies will be asked to report the presence or absence of women and their rate of perceived exertion at each session in a register (reported by the PA professional for ACTI-VISIO; completion, content consultation and validation statistics; PA level and number of days the activity bracelet is worn for ACTI-MOBIL).

Motivation for PA. The motivation for health-oriented PA will be measured with a French motivation scale for health-oriented PA.59 This scale comprises 18 items, distributed across the six motivational constructs of the self-determination theory55: intrinsic motivation, integrated regulation, identified regulation, introjected regulation, external regulation and amotivation. Participants will respond on a 7-point Likert scale ranging from 1 ‘strongly disagree’ to 7 ‘strongly agree’.

General Causality Orientations Scale for PA. Causality orientations will be measured using an adaptation of the General Causality Orientations Scale60 to assess the strength of three motivational orientations (ie, autonomy, control and impersonal) in the context of PA in a medical environment. The scale comprises seven vignettes and 21 items. Each vignette describes a situation and is followed by three items, one per motivational orientation, to which participants respond on a 7-point scale ranging from 1 ‘strongly disagree’ to 7 ‘strongly agree’.

Basic psychological needs. Basic psychological needs will be measured using a French scale validated in the sports context,61 for which we replaced ‘sport’ by ‘physical activity’. This scale comprises 15 items distributed across the three needs: autonomy, competence and relatedness. Participants will respond on a 7-point Likert scale ranging from 1 ‘strongly disagree’ to 7 ‘strongly agree’.

Interventions

All interventions are similar in terms of the recommended PA level: at least 150 min per week, with a goal of 300 min per week of moderate to vigorous PA including muscle strengthening exercises 2–3 times per week.3 The
technology groups will receive similar PA programmes two times a week for 12 weeks (between T0 and T3), combined with advice and counselling about walking activities to achieve the recommendations.

**Control group**
The control group will receive the usual care (also provided to the ACTI-VISIO and ACTI-MOBIL groups) that includes two individual motivational interviews with a PA professional and a group workshop during the first year following BS to help participants achieve the PA recommendations. No face-to-face PA sessions will be offered as part of the usual care.

**ACTI-VISIO group**
The PA sessions will be delivered via a videoconferencing system developed by Mooven. The PA programme consists of tailored adapted PA sessions led by a professional specialised in adapted PA. These sessions were specifically designed to be appropriate for the population and to ensure standardisation of the recommended volume of PA. The PA sessions will be given live, individually at the beginning and then in groups of four women. During sessions, all participants are able to see and interact with each other and with the professional. The execution of the exercises will be monitored and adapted live by the professional. The interactions between participants may constitute a form of peer support. To ensure the safety of the PA, a rating of perceived exertion will be requested after each session on a 10-point scale. If the rating exceeds seven, the professional specialised in adapted PA will adjust the training load. In addition, the sessions will also include advice and tips for reaching the recommended PA level. After randomisation, the women will receive registration details to create a personal account. Participants will then have to select practice times for two sessions per week. Technical assistance will be provided in cases of configuration difficulties. For participants who are absent from a scheduled session, a reminder will be made by phone for the next session.

**ACTI-MOBIL group**
The PA sessions will be delivered by an eHealth platform associated with the Fitbit Inspire activity bracelet. The eHealth platform is a bariatric online module developed by BePatient in collaboration with the authors to enrich PA content and ensure standardisation of the recommended volume of PA. The module used in the present trial consists of tips for reaching the PA level, PA questionnaires, PA feedback measured by the activity bracelet and a video demonstration of PA sessions performed by a peer. To ensure the safety of the PA, the sessions were designed to be appropriate for this population, and the rating of perceived exertion will be measured after each session on a 10-point scale. If the rating exceeds seven for three consecutive sessions, the training load will be adjusted. The platform will also include a variety of content, including dietary tips, obesity-related facts, information about surgery and frequently asked questions. After randomisation, the women will receive registration details to create a personal account, and their activity bracelets will be synchronised with the platform to visualise their PA. Technical support will be provided in cases of configuration or synchronisation difficulties. For the women whose activities have not been detected on the platform 1 week after the start of the programme, a reminder will be given by phone.

**Data analysis and management**

**Sample size**
Sample size for the study is based on the distance travelled during a 6MWT relativised with age, sex and body mass index. A recent meta-analysis showed an overall effect $Z=2.52$ ($p=0.01$) of change in walking distance after BS in an exercise group compared with a control group. An overall effect $Z=2.52$ corresponds to $f=0.20$. However, this effect size is probably minimised because it has not been relativised according to body mass index. Furthermore, eHealth PA programmes for obese or sedentary individuals have an effect size of $d=0.37$, corresponding to $f=0.19$. However, only 45% of eHealth interventions are based on theoretical models, which reduces their effectiveness. Given these limitations, a slightly larger effect size of $f=0.25$ is considered. A total of 108 participants will be necessary to keep a power of 80% and alpha of 5%. We anticipate that 10% of the participants will be lost to follow-up, drop out of testing, withdraw informed consent or be excluded from the study. Thus, with 120 women in each group, we consider our study to be sufficiently powered.

**Data management**
The recruiting clinicians will keep a register with a study number and all identifiable data (name, phone number, pseudonymisation code and allocation group) for use during the follow-up. This register will be locked up with access only available to project investigators. Other data collected will be stored on a secured server with pseudonymisation codes and no other personally identifiable information. The Department of Technology Systems at the University in collaboration with the Public Health Department of the University Hospital will handle the data management. To ensure the quality of the research, an audit may be carried out at any time by the Public Health Department of the University Hospital.

**Data analysis**
The level of significance for all statistical analyses will be set at 0.05 under the bilateral hypothesis. Missing data patterns will be analysed and described. Less than 5% missing data are usually considered inconsequential, and simple methods will be used (e.g. last observation carried forward, mean, median). If more than 5% of the data are missing, these data will be handled by multiple imputation or maximum likelihood imputation. The planning, implementation, analyses and final writing
of the results will follow the recommendations of the CONSORT statements.69

The normality of quantitative data will be assessed using a graphical method and a Shapiro test.70 Simple mathematical transformations can be used if necessary to normalise non-normal data. The dimensional consistency of the subjective data will be calculated using Cronbach’s alpha coefficient. Baseline differences between groups (eg, age, type of surgery, forms of motivation) will be tested prior to hypothesis testing. To test the hypotheses, a mixed model procedure will be used. It should be noted that mixed models are highly recommended for repeated measurement analyses to take into account the non-independence of the repeated measures.71 72 Moreover, the mixed models can be used to analyse longitudinal mediat ed data.73 The repeated measures will be considered as a longitudinal fixed factor. The condition (ACTI-MOBIL, ACTI-VISIO, CONTROL) representing the criterion of the analysis (the independent variable) will be considered as a fixed effect in the model. The intercept will be defined as a random factor that can vary for each participant. The acceptability of technologies and motivational constructs will be the mediating variables added to the mixed model.

ETHICS AND DISSEMINATION

This study was reviewed and approved by the French East 1 Protection of Persons Ethics Committee (number: 2020.A00172-37) and the French National Commission for Information Technology and Civil Liberties (number: UCA-R20-034). This study was registered with ClinicalTrials.gov Identifier (Registered 15 July 2020). The protocol (V.3, 15 October 2020) conforms to the principles of Good Clinical Practice and the Declaration of Helsinki and will be reported according to the 2013 SPIRIT statement74 (online supplemental additional file 3). Any modification of the research protocol must be subjected to an authorisation agreement from the Ethics Committee.

The data sets generated during the current study will be available from the corresponding author on reasonable request and archived for a period of 15 years.

A final scientific report of the research project, including the results and clinical outcomes of the study, will be written by the principal investigator and sent to the Ethics Committees within 1 year of the research conclusion. Research summary results will be available to participants in accordance with the terms described in the information documents. The results of this trial will be disseminated through conference presentations and in peer-reviewed journals.

DISCUSSION

This study will provide insight into the effects of two technology-based PA programmes (mobile technology and videoconferencing) post-BS. This study will also provide a better understanding of the acceptability and motivational constructs in mediating the effects of these technologies. Based on the results, strategies to individually promote technology-based PA interventions and recommendations for implementing these programmes will be developed.

Author affiliations

1Laboratoire Motricité Humaine Expertise Sport Santé (LAMHESS), Université Côte d’Azur, Nice, France
2Centre Spécialisé Obésité PACA Est, Centre Hospitalier Universitaire de Nice Pole Digestif Addictologie Reanimation chirurgicale Endocrinologie, Nice, France
3Département de Santé Publique, Centre Hospitalier Universitaire de Nice, Nice, France
4Laboratoire d’Anthropologie et de Psychologie Cliniques, Cognitives et Sociales (LAPCOS), Université Côte d’Azur, Nice, France
5Association Azur Sport Santé, Nice, France

Twitter Meggy Hayotte @HayotteMeggy

Acknowledgements We sincerely thank Juni Grip and David Fuente for their valuable assistance in developing the content and their collaboration with the companies. We express our gratitude to Be Patient and Mooven for their involvement in this trial (content of the interventions can be shared on request from the companies, without guaranteeing the absence of fees).

Contributors Fd’AL, MH and VN conceived the project and procured the project funding. NC, AI, CP, SSC, AF and PT contributed to the trial protocol. OD, J-MG, AV, SSC and MH conceptualised the interventions, developed the contents, and worked with the companies. Fd’A-L is leading the coordination of the trial. NC and AI are managing the trial including recruitment and data collection with the assistance of VN and MH. CP, Fd’AL, and MH developed the plan for statistical analysis. MH and Fd’AL drafted the manuscript and coordinated the revisions. All other authors reviewed, edited and approved the final manuscript.

Funding This work was supported by the French government, managed by the ‘Agence Nationale de la Recherche’ as part of the UCAJEDI Future Investments project, reference number ANR-15-IDEX-01. The UCAJEDI Future Investments project had a role neither in the design of the study, data collection, analysis and interpretation of the data nor in writing this manuscript or the decision to publish the manuscript. MH is supported by a PhD grant from the Région Sud Provence-Alpes Côte d’Azur, France and co-supported by the association ‘Azur Sport Santé’. The Région Sud Provence-Alpes Côte d’Azur had a role neither in the design of the study, data collection, analysis and interpretation of the data nor in writing this manuscript or the decision to publish the manuscript. The association ‘Azur Sport Santé’ is a non-profit entity that had no financial interest in this study. Based on their previous experience in clinical trials, the association contributed to the trial protocol, but they had a role neither in the collection, analysis and interpretation of data nor in the decision to publish the manuscript.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
REFERENCES


63 Lenhard W, Lenhard A. Calculation of effect sizes. Dettelbach (Germany, 2016).
Additional file 1. Management of adverse events

1. Definition

**Adverse event (AE)** (article R1123-46 of the public health code): Any harmful event occurring in a person who undergoes research, whether or not this event is related to the research or the product on which this research is based.

**Serious Adverse Event / Effect (SAE)** (article R1123-46 of the public health code and ICH E2B guide):

- Leads to death.
- Endangers the life of the person undergoing the research.
- Leads to hospitalization or prolongation of hospitalization.
- Leads to significant or lasting disability or handicap.
- Results in a congenital anomaly or malformation.
- Does not meet the qualifications listed above but may be considered "potentially serious" (certain biological abnormalities), is considered a relevant drug in the judgment of the investigator, and requires medical intervention to prevent progression to a precipitous condition.

The term "life-threatening" is reserved for an immediate life-threatening situation at the time of the adverse event, regardless of the consequences of corrective or palliative therapy.

**Unexpected Adverse Reaction (UAR):** Any adverse reaction whose nature, severity or course is not consistent with the information contained in the guidelines recognized by the authorities.

**Suspected Unexpected Severe Adverse Reaction (SUSAR):** An adverse reaction whose nature, severity/intensity or course is not consistent with the information contained in Investigator's Brochure or Protocol.

**Expected Serious Adverse Effect (EIGA):** Any effect defined in the protocol as expected.

**New fact** (article R1123-46 of the public health code): Any new data that may lead to a reassessment of the benefit/risk ratio of the product under investigation, to changes in the use of this product, in the conduct of the research, or in the documents relating to the research, or to the suspension or interruption or modification of the research protocol or similar research.

The following will NOT be considered as an SAE:

- An event resulting in a transient move to a hospital consultation, door-to-door service, or day hospital.
- Hospitalizations (more than one night on site) or prolongations of hospitalizations for the following reasons:
  - Scheduled hospitalization for routine procedures or treatments that are part of a pre-defined monitoring or therapy program.
  - Hospitalization or intervention required by protocol.
  - Hospitalization for comfort or for a social reason (e.g., hospitalization of an elderly person in a relationship of dependence with a spouse who has just been hospitalized).
  - Elective hospitalization not associated with a worsening of the clinical condition and not related to the objective of the clinical study and taking place during the clinical study (e.g., cosmetic surgery).
  - Infectious complications treated on an outpatient basis and not leading to hospitalization.
2. Types of adverse events
   **Risks related to bariatric surgery:**
   In the event of too much stress during physical activity due to the very reduced food intake and rapid weight loss, vagal discomfort, benign dizziness, and functional hypoglycemia may rarely occur. Dumping syndrome, a discomfort specifically linked to bariatric surgery, could potentially occur during physical activity without any direct link with it.

   **Expected risks related to the study procedures:**
   Muscle contractures may occur during the physical activity program or during the 6-minute walk test.

3. Behavior to be observed
   In order to avoid the occurrence of an adverse event, patients are asked not to carry out the exercises alone, to always have someone close to them available in case of an adverse event and, especially if discomfort has already occurred, to be attentive to the first signs in order to adopt the appropriate course of action.

   The action to be taken for each adverse event is:

   **Vagal malaise or functional hypoglycemia:** the patient becomes pale during exercise and more often during recovery, may complain of nausea and lightheadedness, may present sweating and hot flashes, and describes sudden fatigue.
   1. Stop the effort.
   2. Lie flat with legs elevated or bent.
   3. Notify a doctor (call 15).

   **Dumping syndrome:** the patient becomes pale, has hot flashes, sweats, palpitations and tachycardia, and complains of abdominal pain or gagging.
   1. Stop the effort.
   2. Lie flat with legs raised or bent.
   3. In conjunction with the health care team, adapt dietary and behavioral measures (e.g., increase time allocated to eating, avoid foods identified as triggers, limit simple sugars in favor of complex sugars (Di Vetta et al., 2017).

4. Procedures for recording and reporting adverse events
   Any non-serious adverse event, as defined above, observed during the research and its aftermath must be reported in the observation book in the section provided for this purpose. Only one event should be reported per item. The event may correspond to a symptom, a diagnosis or a result of a complementary examination deemed significant. All clinical or paraclinical elements that best describe the corresponding event must be reported.

   A form for reporting a serious adverse event, validated for research, and a classification grid for serious and non-serious adverse events will be made available to the persons involved in the research protocol to help them manage adverse events (i.e., to help them differentiate between events according to their seriousness and their expected nature). The grid will be drawn up and validated by all those involved in the research. It may be modified during the course of the research, depending on the reports received by the sponsor.

   The sponsor, informed by the intervener, is obliged to notify the Steering Committee immediately of all serious adverse events except those listed in the grid as not requiring immediate notification. For each serious adverse event, the Steering Committee must issue an opinion on the causal link of the event with any experimental element of the research, whether it concerns the procedures performed or the products used. Obtaining information relating to the description and evaluation of an adverse event may not be possible within the time allowed for the initial report. Therefore, the clinical course, as well as the results of any clinical check-ups and diagnostic and/or laboratory examinations, or any other information allowing an adequate analysis of the causal link, will be reported:
• Either on the initial report of the SAE if they are immediately available.
• Or subsequently and as quickly as possible, by sending a new completed SAE report by fax (and specifying that it is a follow-up to a declared SAE and the follow-up number).

All reports made by investigators should identify each subject participating in the research by a unique code number assigned to each subject.
In the event of a notified death of a research subject, the investigator should provide the sponsor with any additional information requested (e.g., hospital report, autopsy results).
Any new fact occurring in the research or in the context of the research, from data in the literature or from ongoing research, must be notified to the sponsor.

5. Reporting of adverse events to the Health Authorities
All suspected serious unexpected adverse events will be reported by the sponsor to the competent authorities within the legal deadlines.
In the event of a serious unexpected adverse reaction due to an experimental element of the research, whether it concerns the procedures performed or the products used, the competent authorities, the Personal Protection Committee and the research investigators must be informed.

6. Follow-up procedures for individuals following the occurrence of adverse events
Any patient presenting an adverse event should be followed up until the event is resolved or stabilized. If the event is not serious, the progress of the event should be noted on the relevant page of the case report form in the section provided for this purpose.
INFORMATION NOTICE FOR PATIENTS FOR PARTICIPATION IN THE OCAPAS STUDY

Study of Physical Activity and Bariatric Surgery

Research title: “OCAPAS” Scientific study

Trial sponsor: Côte d’Azur University
Head of research: Prof. Fabienne d’Arripe-Longueville, Laboratoire Motricité Humaine, Expertise, Sport Santé [Laboratory of Human Motricity, Expertise, Sport, and Health] (EA 6312), Côte d’Azur University
Principal investigators: Prof. Nicolas Chevalier, University Professor – Hospital Practitioner at the Nice University Hospital; Prof. Antonio Ianneli, University Professor – Hospital Practitioner at the Nice University Hospital

Madam,
We would like to offer you the opportunity to participate in a clinical research study because you are undergoing a bariatric surgery procedure. This information notice will tell you more about the study. You have a 7-day reflection period during which you can take the time to read and understand this information, reflect on your participation, and ask the principal investigators of the study to explain what you did not understand.

PURPOSE OF THE STUDY
The “OCAPAS” scientific study is conducted in partnership with the Laboratoire Motricité Humaine, Expertise, Sport, Santé (LAMHESS) of Côte d’Azur University, the Specialised Obesity Center of the Provence Alpes Côte d’Azur East, the DARE [Digestive-Anesthesia-Resuscitation-Endocrinology] pole of the Nice University Hospital, the Public Health Department of the Nice University Hospital, Azur Sport Santé, the Laboratoire d’Anthropologie, Psychologie Cliniques, Cognitives et Sociales (LAPCOS) [Laboratory of Anthropology, Clinical, Cognitive and Social Psychology] of Côte d’Azur University, and the companies Be Patient and Mooven.
Its main objective is to study patient engagement in physical activity during bariatric surgery follow-up.
The secondary objectives are to study the impact of your physical activity practice on different engagement and health indicators. Your perception of various mechanisms which could help to strengthen your commitment to physical activity will also be measured.
ANTICIPATED BENEFIT(S)
This study, through the physical activity that will be recommended to you, should help improve your health, quality of life and well-being.

CONDUCTING THE STUDY
You will be monitored through physical and psychological assessments. You will be included in a group at random. This random selection will be made by the person in charge of the study as soon as you return this information letter and the signed consent form. In order to guarantee the scientific validity of the study, you will then receive the information corresponding to the group in which you are assigned. Assessments will take place upon inclusion in a group (T0), then at 3 months (T3), and 6 months (T6) after inclusion. Only the physical assessments requiring a measurement will be required to take place at the Archet 2 University Hospital in Nice. Physical assessments will be based on a 6-minute walking test (carried out under standardised conditions), a strength test, and the wearing of an accelerometer for 7 days positioned at the time of the assessments (and returned at the end of the 7-day period by post with a stamped envelope provided). Height, weight and impedance measurements will be carried out by a doctor or nurse as part of the standard monitoring.

The questionnaires to which you will be submitted can be filled in online on the LimeSurvey platform. You will receive an e-mail with the link to the questionnaire and a reminder of your anonymity number. If you have difficulty completing the questionnaires on the LimeSurvey platform, you can also complete them on paper during the physical assessments. The questionnaires will be used to evaluate:

- Self-reported physical activity level
- Observance and motivation:
  - The number, duration and type of physical activity sessions per week according to international recommendations.
  - Physical exercise habits and history
  - The stage of engagement in practice
  - Motivation for physical activity, how you feel during physical activity, and your reactions to various situations.
- Your perception of the solution to strengthen your commitment to physical activity
- Quality of life and health.

POTENTIAL RISKS
The respect of the protocol and contra-indications, the specific training of the adapted physical activity professional, as well as the carrying out of the evaluations at the Archet 2 Nice University Hospital, will guarantee your safety during the evaluations. The risks that may arise during these assessments are those of possible and classic discomforts during the sessions (vaso-vagal episode, drop in blood pressure, shortness of breath, dizziness)
Information notice – pre-registration phase (all) – V4 (15/10/2020)
ID No. – RCB: 2020-A00172-37

for which the assessors are trained and which are the same as those related to practising physical or sports activities of daily life. However, the scientific committee reserves the right to terminate the experiment in case of poor adaptation or intolerance.

CONSTRAINTS
You are free to participate in another research protocol, provided it does not involve new technologies and does not have an impact on physical activity levels or fitness measurement.

FINANCIAL PARTICIPATION
Your collaboration in this research protocol will not involve any financial participation on your part.
All costs (medical, supervision, equipment, insurance, etc.) related to the study will be covered by the researchers.
Only an uncashed cheque used as a security deposit for the loan of the equipment will be requested from you and then destroyed upon the return of the equipment.

LEGISLATION - CONFIDENTIALITY
In accordance with Articles L. 1121-1 et seq. of the French Public Health Code, the Committee on Human Research studied this research project and issued a favourable opinion on 01/04/2020.
An insurance policy, number 146 177 524, was taken out by the sponsor of the trial, the Côte d'Azur University - 20 avenue Valrose - BP 2135 - 06103 Nice Cedex 2, with the company MMA Entreprise, to cover the risks linked to this research.
Any information about you collected during this trial will be treated confidentially. Only those responsible for the study and possibly the health authorities will have access to this data. With the exception of these people - who will treat the information in the strictest respect of medical secrecy - your anonymity will be preserved. The publication of the results of the study will not include any individual results.
The data recorded over the course of this study will be subject to computerised processing by the sponsor. As this is personal data, you have the right of access, rectification, portability, deletion or limitation in the processing of data concerning you at any time by contacting the Data Protection Officer, Mr. Didier Martin at the Côte d'Azur University and those in charge of the study. As regards information of a medical nature, this right is exercised through the intermediary of Professor Nicolas Chevalier at the University Hospital of Nice, in accordance with France’s law on Information Technology, Data Files and Civil Liberties, No. 78-17 of 6 January 1978, amended by law No. 94-548 of the 1st of July 1994, and Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of individuals with regard to the processing of personal data and on the free movement of such data and repealing Directive 95/46/EC (General Data Protection Regulation). The project received a
Information notice – pre-registration phase (all) – V4 (15/10/2020)
ID No. – RCB: 2020-A00172-37

notification of compliance with reference to methodology, and an analysis of the impact on privacy delivered by the Data Protection Officer of the Côte d’Azur University on 28/04/2020. In accordance with Article L. 1122-1, as amended, of the French Public Health Code (law of March 2002 on patients’ rights), the overall results of the study can be communicated to you if you wish.

If you have any questions during your participation in this study, you may contact the principal investigators of this study:
- Prof. Nicolas Chevalier, phone: 04.92.03.55.19 at the Archet 2 University Hospital of Nice
- Prof. Antonio Iannelli, phone: 04.92.03.55.19 at the Archet 2 University Hospital of Nice

Or the scientific head of research:
- Prof. Fabienne d’Arripe-Longueville, phone: 04.89.15.39.55 at the LAMHESS of the Côte d’Azur University.

Or the Data Protection Officer:
- Mr. Didier Martin, phone: 04.89.15.11.99 at the Côte d’Azur University

You are free to accept or refuse to participate in this study. This will in no way affect the quality or the level of care you will receive, which will be the same as it has been thus far. During the course of the study, you may also decide to discontinue your participation without having to justify your decision.

Thank you for taking the time to read this newsletter. If you agree to participate in this research study, we invite you to sign the attached consent form.
CONSENT FORM
FOR PARTICIPATION IN THE OCAPAS STUDY

Study on Physical Activity and Bariatric Surgery

Research title: “OCAPAS” Scientific study

I, the undersigned, accept to participate in the “OCAPAS” study.

The objectives and terms of the study were clearly explained to me by Prof. Nicolas Chevalier and Prof. Antonio Iannelli.

I have read and understood the information sheet given to me.

I accept that the documents in my medical file that relate to the study may be accessible to those responsible for the study and possibly to the health authorities. With the exception of these persons, who will treat the information in the strictest respect of medical confidentiality, my anonymity will be preserved.

I accept that my personal data collected during this study may be subject to automated processing by the research organisers. I may exercise my right of access, rectification, portability, deletion or limitation of the processing of data concerning me by contacting the data protection representative Mr. Didier Martin at the Côte d’Azur University, and as regards information of a medical nature by contacting Professor Nicolas Chevalier at the Nice University Hospital.

I understand that my participation in the study is voluntary.

I am free to accept or refuse to participate, and I am free to stop my participation at any time during the course of the study. This will not affect the quality of care I will receive.

My consent does not relieve the organisers of this study of their responsibilities. I retain all my rights under the law.

Having discussed it and having obtained the answers to all my questions, I freely and voluntarily agree to participate in the research study proposed to me.

Prepared in Nice, on __/__/____

Name and signature of the investigator

Signature of the volunteer
Information notice – ACTI-MOBIL Group – V4 (15/10/2020)
ID No. – RCB: 2020-A00172-37

INFORMATION NOTICE FOR PATIENTS
FOR PARTICIPATION IN THE OCAPAS STUDY

Study of Physical Activity and Bariatric Surgery

Research title: “OCAPAS” Scientific study

Trial sponsor: Côte d’Azur University
Head of research: Prof. Fabienne d’Arripe-Longueville, Laboratoire Motricité Humaine, Expertise, Sport Santé [Laboratory of Human Motricity, Expertise, Sport, and Health] (EA 6312), Côte d’Azur University
Principal investigators: Prof. Nicolas Chevalier, University Professor – Hospital Practitioner at the Nice University Hospital; Prof. Antonio Iannelli, University Professor – Hospital Practitioner at the Nice University Hospital

Madam,

We would like to offer you the opportunity to participate in a clinical research study because you are undergoing a bariatric surgery procedure.

This information notice will tell you more about the study.

You have a 7-day reflection period during which you can take the time to read and understand this information, reflect on your participation, and ask the principal investigators of the study to explain what you did not understand.

PURPOSE OF THE STUDY

The “OCAPAS” scientific study is conducted in partnership with the Laboratoire Motricité Humaine, Expertise, Sport, Santé (LAMHESS) of Côte d’Azur University, the Specialised Obesity Center of the Provence Alpes Côte d’Azur East, the DARE [Digestive-Anesthesia-Resuscitation-Endocrinology] pole of the Nice University Hospital, the Public Health Department of the Nice University Hospital, Azur Sport Santé, the Laboratoire d’Anthropologie, Psychologie Cliniques, Cognitives et Sociales (LAPCOS) [Laboratory of Anthropology, Clinical, Cognitive and Social Psychology] of Côte d’Azur University, and the companies Be Patient and Mooven.

Its main objective is to study patient engagement in physical activity during bariatric surgery follow-up. To support your commitment to physical activity, the MyBody mobile application proposed by Be Patient will be made available to you.

The secondary objectives are to study the impact of your physical activity practice on different engagement and health indicators. Your perception of various mechanisms which could help to strengthen your commitment to physical activity will also be measured.
ANTICIPATED BENEFIT(S)
This study, through the physical activity that will be recommended to you, should help improve your health, quality of life and well-being.

CONDUCTING THE STUDY
To support your commitment to physical activity, you will benefit from the MyBody mobile application proposed by Be Patient and a connected watch that will allow you to view the number of steps you’ve taken each day, week and month. The mobile application is composed of advice sheets with quizzes, and a guided adapted physical activity program to be begun between the 3rd and 6th month following bariatric surgery. The adapted physical activity programme will respect international recommendations, i.e. it will accompany you in achieving 150 minutes per week with the goal of reaching 300 minutes per week. On the mobile application, you will be proposed two sessions per week, lasting from 30 to 50 minutes, consisting of endurance exercises and resistance strength-conditioning exercises in the form of a training circuit which will evolve progressively over the course of the programme. In addition, you will also be encouraged to walk regularly so as to reach the recommendations. After each session, you will record your participation on the application and evaluate your rating of perceived exertion on a scale from 0 to 10.
You will be monitored through physical and psychological assessments in the form of questionnaires. Assessments will take place at the beginning of inclusion (T0), then at 3 months (T3), and 6 months (T6) after inclusion. Only the physical assessments requiring a measurement will be required to take place at the Archet 2 University Hospital in Nice.

Physical assessments will be based on a 6-minute walking test (carried out under standardised conditions), a strength test, and the wearing of an accelerometer for 7 days positioned at the time of the assessments (and returned at the end of the 7-day period by post with a stamped envelope provided). Height, weight and impedance measurements will be carried out by a doctor or nurse as part of the standard monitoring.
The questionnaires to which you will be submitted can be filled in online on the LimeSurvey platform. You will receive an e-mail with the link to the questionnaire and a reminder of your anonymity number. If you have difficulty completing the questionnaires on the LimeSurvey platform, you can also complete them on paper during the physical assessments. The questionnaires will be used to evaluate:
- Self-reported physical activity level
- Observance and motivation:
  - The number, duration and type of physical activity sessions per week according to international recommendations.
  - Physical exercise habits and history
  - The stage of engagement in practice
  - Motivation for physical activity, how you feel during physical activity, and your reactions to various situations.
Your perception of the solution to strengthen your commitment to physical activity
- Quality of life and health.

**POTENTIAL RISKS**
The respect of the protocol and contra-indications, the specific training of the adapted physical activity professional, as well as the carrying out of the evaluations at the Archet 2 Nice University Hospital, will guarantee your safety during the evaluations.
The risks that may arise during these assessments are those of possible and classic discomforts during the sessions (vaso-vagal episode, drop in blood pressure, shortness of breath, dizziness) for which the assessors are trained and which are the same as those related to practising physical or sports activities of daily life.
When carrying out the physical activities guided by the mobile application, the recommended perceived intensity must be strictly respected so as to avoid any risk during the practice (vaso-vagal episode, drop in blood pressure, shortness of breath...). Even if the risk of occurrence is low, it is advisable to always have a trusted person nearby to be able to react in the event of an undesirable event.
However, the scientific committee reserves the right to terminate the experiment in case of poor adaptation or intolerance.

**CONSTRAINTS**
You are free to participate in another research protocol, provided it does not involve new technologies and does not have an impact on physical activity levels or fitness measurement.

**FINANCIAL PARTICIPATION**
Your collaboration in this research protocol will not involve any financial participation on your part.
All costs (medical, supervision, equipment, insurance, etc.) related to the study will be covered by the researchers.
Only an uncashed cheque used as a security deposit for the loan of the equipment will be requested from you and then destroyed upon the return of the equipment.

**LEGISLATION - CONFIDENTIALITY**
In accordance with Articles L. 1121-1 et seq. of the French Public Health Code, the Committee on Human Research studied this research project and issued a favourable opinion on 01/04/2020.
An insurance policy, number 146 177 524, was taken out by the sponsor of the trial, the Côte d'Azur University - 20 avenue Valrose - BP 2135 - 06103 Nice Cedex 2, with the company MMA Enterprise, to cover the risks linked to this research.
Any information about you collected during this trial will be treated confidentially.
Only those responsible for the study and possibly the health authorities will have access to this data. With the exception of these people - who will treat the information in the strictest
Information notice – ACTI-MOBIL Group – V4 (15/10/2020)
ID No. – RCB: 2020-A00172-37

respect of medical secrecy - your anonymity will be preserved. The publication of the results of the study will not include any individual results.

The data recorded over the course of this study will be subject to computerised processing by the sponsor. As this is personal data, you have the right of access, rectification, portability, deletion or limitation in the processing of data concerning you at any time by contacting the Data Protection Officer, Mr. Didier Martin at the Côte d'Azur University and those in charge of the study. As regards information of a medical nature, this right is exercised through the intermediary of Professor Nicolas Chevalier at the University Hospital of Nice, in accordance with France’s law on Information Technology, Data Files and Civil Liberties, No. 78-17 of 6 January 1978, amended by law No. 94-548 of the 1st of July 1994, and Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of individuals with regard to the processing of personal data and on the free movement of such data and repealing Directive 95/46/EC (General Data Protection Regulation). The project received a notification of compliance with reference to methodology, and an analysis of the impact on privacy delivered by the Data Protection Officer of the Côte d’Azur University on 28/04/2020. In accordance with Article L. 1122-1, as amended, of the French Public Health Code (law of March 2002 on patients' rights), the overall results of the study can be communicated to you if you wish.

If you have any questions during your participation in this study, you may contact the principal investigators of this study:
- Prof. Nicolas Chevalier, phone: 04.92.03.55.19 at the Archet 2 University Hospital of Nice
- Prof. Antonio Iannelli, phone: 04.92.03.55.19 at the Archet 2 University Hospital of Nice

Or the scientific head of research:
- Prof. Fabienne d’Arripe-Longueville, phone: 04.89.15.39.55 at the LAMHESS of the Côte d’Azur University.

Or the Data Protection Officer:
- Mr. Didier Martin, phone: 04.89.15.11.99 at the Côte d’Azur University

You are free to accept or refuse to participate in this study. This will in no way affect the quality or the level of care you will receive, which will be the same as it has been thus far. During the course of the study, you may also decide to discontinue your participation without having to justify your decision.

Thank you for taking the time to read this newsletter. If you agree to participate in this research study, we invite you to sign the attached consent form.
CONSENT FORM
FOR PARTICIPATION IN THE OCAPAS STUDY
Study on Physical Activity and Bariatric Surgery

Research title: “OCAPAS” Scientific study

I the undersigned ............................................................. (Last name and first name of the volunteer), accept to participate in the “OCAPAS” study.
The objectives and terms of the study were clearly explained to me by Prof. Nicolas Chevalier and Prof. Antonio Iannelli.
I have read and understood the information sheet given to me.
I accept that the documents in my medical file that relate to the study may be accessible to those responsible for the study and possibly to the health authorities. With the exception of these persons, who will treat the information in the strictest respect of medical confidentiality, my anonymity will be preserved.
I accept that my personal data collected during this study may be subject to automated processing by the research organisers. I may exercise my right of access, rectification, portability, deletion or limitation of the processing of data concerning me by contacting the data protection representative Mr. Didier Martin at the Côte d’Azur University, and as regards information of a medical nature by contacting Professor Nicolas Chevalier at the Nice University Hospital.
I understand that my participation in the study is voluntary.
I am free to accept or refuse to participate, and I am free to stop my participation at any time during the course of the study. This will not affect the quality of care I will receive.
My consent does not relieve the organisers of this study of their responsibilities. I retain all my rights under the law.
Having discussed it and having obtained the answers to all my questions, I freely and voluntarily agree to participate in the research study proposed to me.

Prepared in Nice, on __/__/____

Name and signature of the investigator

Signature of the volunteer
INFORMATION NOTICE FOR PATIENTS
FOR PARTICIPATION IN THE OCAPAS STUDY

Study of Physical Activity and Bariatric Surgery

Research title: “OCAPAS” Scientific study

Trial sponsor: Côte d'Azur University
Head of research: Prof. Fabienne d'Arripe-Longueville, Laboratoire Motricité Humaine, Expertise, Sport Santé [Laboratory of Human Motricity, Expertise, Sport, and Health] (EA 6312), Côte d'Azur University
Principal investigators: Prof. Nicolas Chevalier, University Professor – Hospital Practitioner at the Nice University Hospital; Prof. Antonio Iannelli, University Professor – Hospital Practitioner at the Nice University Hospital

Madam,
We would like to offer you the opportunity to participate in a clinical research study because you are undergoing a bariatric surgery procedure.
This information notice will tell you more about the study.
You have a 7-day reflection period during which you can take the time to read and understand this information, reflect on your participation, and ask the principal investigators of the study to explain what you did not understand.

PURPOSE OF THE STUDY
The “OCAPAS” scientific study is conducted in partnership with the Laboratoire Motricité Humaine, Expertise, Sport, Santé (LAMHESS) of Côte d'Azur University, the Specialised Obesity Center of the Provence Alpes Côte d’Azur East, the DARE [Digestive-Anesthesia-Resuscitation-Endocrinology] pole of the Nice University Hospital, the Public Health Department of the Nice University Hospital, Azur Sport Santé, the Laboratoire d'Anthropologie, Psychologie Cliniques, Cognitives et Sociales (LAPCOS) [Laboratory of Anthropology, Clinical, Cognitive and Social Psychology] of Côte d’Azur University, and the companies Be Patient and Mooven.
Its main objective is to study patient engagement in physical activity during bariatric surgery follow-up. To support your commitment to physical activity, adapted physical activity sessions by videoconference will be made available to you.
The secondary objectives are to study the impact of your physical activity practice on different engagement and health indicators. Your perception of various mechanisms which could help to strengthen your commitment to physical activity will also be measured.
ANTICIPATED BENEFIT(S)

This study, through the physical activity that will be recommended to you, should help improve your health, quality of life and well-being.

CONDUCTING THE STUDY

To support your commitment to physical activity, following your bariatric surgery, you will benefit from an adapted physical activity program delivered via videoconferencing by a trained professional. Initially, you will have one-on-one videoconferences with an adapted physical activity professional, and then you will be given the opportunity to participate in group sessions with a group of young women included in this study like you. This group will be composed of a maximum of 4 people. The adapted physical activity program carried out by videoconference will comply with international recommendations, i.e. it will accompany you in achieving 150 minutes per week with the goal of reaching 300 minutes per week. You will be proposed two videoconference sessions per week, lasting from 30 to 50 minutes, consisting of endurance exercises and resistance strength-conditioning exercises in the form of a training circuit which will evolve progressively over the course of the programme. For each exercise, the professional will show you the exercise and explain it to you, and then you will carry out the number of repetitions planned together. As the sessions will be carried out live, the professional will be able to correct your posture and give you advice. In addition, he will encourage you to walk regularly so as to reach the recommendations. After each session, the professional will record your participation on a monitoring form and will ask you to evaluate your rating of perceived exertion on a scale from 0 to 10.

You will be monitored through physical and psychological assessments in the form of questionnaires. Assessments will take place at the beginning of inclusion (T0), then at 3 months (T3), and 6 months (T6) after inclusion. Only the physical assessments requiring a measurement will be required to take place at the Archet 2 University Hospital in Nice.

Physical assessments will be based on a 6-minute walking test (carried out under standardised conditions), a strength test, and the wearing of an accelerometer for 7 days positioned at the time of the assessments (and returned at the end of the 7-day period by post with a stamped envelope provided). Height, weight and impedance measurements will be carried out by a doctor or nurse as part of the standard monitoring.

The questionnaires to which you will be submitted can be filled in online on the LimeSurvey platform. You will receive an e-mail with the link to the questionnaire and a reminder of your anonymity number. If you have difficulty completing the questionnaires on the LimeSurvey platform, you can also complete them on paper during the physical assessments. The questionnaires will be used to evaluate:

- Self-reported physical activity level
- Observance and motivation:
  - The number, duration and type of physical activity sessions per week according to international recommendations.
Information notice – ACTI-VISIO Group – V4 (15/10/2020)
ID No. – RCB: 2020-A00172-37

- Physical exercise habits and history
- The stage of engagement in practice
- Motivation for physical activity, how you feel during physical activity, and your reactions to various situations.
- Your perception of the solution to strengthen your commitment to physical activity
- Quality of life and health.

POTENTIAL RISKS
The respect of the protocol and contra-indications, the specific training of the adapted physical activity professional, as well as the carrying out of the evaluations at the Archet 2 Nice University Hospital, will guarantee your safety during the evaluations.

The risks that may arise during these assessments are those of possible and classic discomforts during the sessions (vaso-vagal episode, drop in blood pressure, shortness of breath, dizziness) for which the assessors are trained and which are the same as those related to practising physical or sports activities of daily life.

When carrying out the physical activities guided by the adapted physical activity professional by videoconference, the recommended perceived intensity must be strictly respected so as to avoid any risk during the session (vaso-vagal episode, drop in blood pressure, shortness of breath...). Even if the risk of occurrence is low, it is advisable to always have a trusted person nearby to be able to react in the event of an undesirable event.

However, the scientific committee reserves the right to terminate the experiment in case of poor adaptation or intolerance.

CONSTRAINTS
You are free to participate in another research protocol, provided it does not involve new technologies and does not have an impact on physical activity levels or fitness measurement.

FINANCIAL PARTICIPATION
Your collaboration in this research protocol will not involve any financial participation on your part.
All costs (medical, supervision, equipment, insurance, etc.) related to the study will be covered by the researchers.
Only an uncashed cheque used as a security deposit for the loan of the equipment will be requested from you and then destroyed upon the return of the equipment.

LEGISLATION - CONFIDENTIALITY
In accordance with Articles L. 1121-1 et seq. of the French Public Health Code, the Committee on Human Research studied this research project and issued a favourable opinion on 01/04/2020.
An insurance policy, number 146 177 524, was taken out by the sponsor of the trial, the Côte d'Azur University - 20 avenue Valrose - BP 2135 - 06103 Nice Cedex 2, with the company MMA Entreprise, to cover the risks linked to this research.

Any information about you collected during this trial will be treated confidentially. Only those responsible for the study and possibly the health authorities will have access to this data. With the exception of these people - who will treat the information in the strictest respect of medical secrecy - your anonymity will be preserved. The publication of the results of the study will not include any individual results.

The data recorded over the course of this study will be subject to computerised processing by the sponsor. As this is personal data, you have the right of access, rectification, portability, deletion or limitation in the processing of data concerning you at any time by contacting the Data Protection Officer, Mr. Didier Martin at the Côte d'Azur University and those in charge of the study. As regards information of a medical nature, this right is exercised through the intermediary of Professor Nicolas Chevalier at the University Hospital of Nice, in accordance with France’s law on Information Technology, Data Files and Civil Liberties, No. 78-17 of 6 January 1978, amended by law No. 94-548 of the 1st of July 1994, and Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of individuals with regard to the processing of personal data and on the free movement of such data and repealing Directive 95/46/EC (General Data Protection Regulation). The project received a notification of compliance with reference to methodology, and an analysis of the impact on privacy delivered by the Data Protection Officer of the Côte d’Azur University on 28/04/2020.

In accordance with Article L. 1122-1, as amended, of the French Public Health Code (law of March 2002 on patients' rights), the overall results of the study can be communicated to you if you wish.

If you have any questions during your participation in this study, you may contact the principal investigators of this study:
- Prof. Nicolas Chevalier, phone: 04.92.03.55.19 at the Archet 2 University Hospital of Nice
- Prof. Antonio Iannelli, phone: 04.92.03.55.19 at the Archet 2 University Hospital of Nice

Or the scientific head of research:
- Prof. Fabienne d'Arripe-Longueville, phone: 04.89.15.39.55 at the LAMHESS of the Côte d’Azur University.

Or the Data Protection Officer:
- Mr. Didier Martin, phone: 04.89.15.11.99 at the Côte d'Azur University

You are free to accept or refuse to participate in this study. This will in no way affect the quality or the level of care you will receive, which will be the same as it has been thus far. During the
course of the study, you may also decide to discontinue your participation without having to justify your decision.

Thank you for taking the time to read this newsletter. If you agree to participate in this research study, we invite you to sign the attached consent form.
CONSENT FORM
FOR PARTICIPATION IN THE OCAPAS STUDY
Study on Physical Activity and Bariatric Surgery

Research title: “OCAPAS” Scientific study

I, the undersigned…………………………………………………………………………… (Last name and first name of the volunteer), accept to participate in the “OCAPAS” study. The objectives and terms of the study were clearly explained to me by Prof. Nicolas Chevalier and Prof. Antonio Jannelli.

I have read and understood the information sheet given to me. I accept that the documents in my medical file that relate to the study may be accessible to those responsible for the study and possibly to the health authorities. With the exception of these persons, who will treat the information in the strictest respect of medical confidentiality, my anonymity will be preserved.

I accept that my personal data collected during this study may be subject to automated processing by the research organisers. I may exercise my right of access, rectification, portability, deletion or limitation of the processing of data concerning me by contacting the data protection representative Mr. Didier Martin at the Côte d’Azur University, and as regards information of a medical nature by contacting Professor Nicolas Chevalier at the Nice University Hospital.

I understand that my participation in the study is voluntary.

I am free to accept or refuse to participate, and I am free to stop my participation at any time during the course of the study. This will not affect the quality of care I will receive. My consent does not relieve the organisers of this study of their responsibilities. I retain all my rights under the law.

Having discussed it and having obtained the answers to all my questions, I freely and voluntarily agree to participate in the research study proposed to me.

Prepared in Nice, on ___/___/_____;

Name and signature of the investigator

Signature of the volunteer
INFORMATION NOTICE FOR PATIENTS
FOR PARTICIPATION IN THE OCAPAS STUDY

Study of Physical Activity and Bariatric Surgery

Research title: “OCAPAS” Scientific study

Trial sponsor: Côte d'Azur University
Head of research: Prof. Fabienne d'Arripe-Longueville, Laboratoire Motricité Humaine, Expertise, Sport Santé [Laboratory of Human Motricity, Expertise, Sport, and Health] (EA 6312), Côte d'Azur University
Principal investigators: Prof. Nicolas Chevalier, University Professor – Hospital Practitioner at the Nice University Hospital; Prof. Antonio Iannello, University Professor – Hospital Practitioner at the Nice University Hospital

Madam,
We would like to offer you the opportunity to participate in a clinical research study because you are undergoing a bariatric surgery procedure.
This information notice will tell you more about the study.
You have a 7-day reflection period during which you can take the time to read and understand this information, reflect on your participation, and ask the principal investigators of the study to explain what you did not understand.

PURPOSE OF THE STUDY
The “OCAPAS” scientific study is conducted in partnership with the Laboratoire Motricité Humaine, Expertise, Sport, Santé (LAMHSS) of Côte d'Azur University, the Specialised Obesity Center of the Provence Alpes Côte d'Azur East, the DARE [Digestive-Anesthesia-Resuscitation-Endocrinology] pole of the Nice University Hospital, the Public Health Department of the Nice University Hospital, Azur Sport Santé, the Laboratoire d'Anthropologie, Psychologie Cliniques, Cognitives et Sociales (LAPCOS) [Laboratory of Anthropology, Clinical, Cognitive and Social Psychology] of Côte d'Azur University, and the companies Be Patient and Mooven.
Its main objective is to study patient engagement in physical activity during bariatric surgery follow-up. To support your commitment to physical activity, you will be monitored and receive advice from the adapted physical activity professional from the bariatric surgery service.
The secondary objectives are to study the impact of your physical activity practice on different engagement and health indicators. Your perception of various mechanisms which could help to strengthen your commitment to physical activity will also be measured.
ANTICIPATED BENEFIT(S)
This study, through the physical activity that will be recommended to you, should help improve your health, quality of life and well-being.

CONDUCTING THE STUDY
To support your commitment to physical activity, you will be monitored and receive advice to help you achieve 150 minutes per week of physical activity with the goal of reaching 300 minutes per week. This advice and recommendations will be given to you by the adapted physical activity professional from the bariatric surgery service. You will be encouraged to walk regularly in order to reach the recommendations and to carry out two sessions per week dedicated to physical activity including muscle strengthening exercises adapted to the bariatric surgery course.

You will be monitored through physical and psychological assessments in the form of questionnaires. Assessments will take place at the beginning of inclusion (T0), then at 3 months (T3), and 6 months (T6) after inclusion. Only the physical assessments requiring a measurement will be required to take place at the Archet 2 University Hospital in Nice.

Physical assessments will be based on a 6-minute walking test (carried out under standardised conditions), a strength test, and the wearing of an accelerometer for 7 days positioned at the time of the assessments (and returned at the end of the 7-day period by post with a stamped envelope provided). Height, weight and impedance measurements will be carried out by a doctor or nurse as part of the standard monitoring.

The questionnaires to which you will be submitted can be filled in online on the LimeSurvey platform. You will receive an e-mail with the link to the questionnaire and a reminder of your anonymity number. If you have difficulty completing the questionnaires on the LimeSurvey platform, you can also complete them on paper during the physical assessments. The questionnaires will be used to evaluate:
- Self-reported physical activity level
- Observance and motivation:
  - The number, duration and type of physical activity sessions per week according to international recommendations.
  - Physical exercise habits and history
  - The stage of engagement in practice
  - Motivation for physical activity, how you feel during physical activity, and your reactions to various situations.
- Your perception of the solution to strengthen your commitment to physical activity
- Quality of life and health.
**POTENTIAL RISKS**
The respect of the protocol and contra-indications, the specific training of the adapted physical activity professional, as well as the carrying out of the evaluations at the Archet 2 Nice University Hospital, will guarantee your safety during the evaluations.
The risks that may arise during these assessments are those of possible and classic discomforts during the sessions (vaso-vagal episode, drop in blood pressure, shortness of breath, dizziness) for which the assessors are trained and which are the same as those related to practising physical or sports activities of daily life.
When carrying out the recommended physical activities, the recommended perceived intensity must be strictly respected so as to avoid any risk during the practice (vaso-vagal episode, drop in blood pressure, shortness of breath...).
However, the scientific committee reserves the right to terminate the experiment in case of poor adaptation or intolerance.

**CONSTRAINTS**
You are free to participate in another research protocol, provided it does not involve new technologies and does not have an impact on physical activity levels or fitness measurement.

**FINANCIAL PARTICIPATION**
Your collaboration in this research protocol will not involve any financial participation on your part.
All costs (medical, supervision, equipment, insurance, etc.) related to the study will be covered by the researchers.
Only an uncashed cheque used as a security deposit for the loan of the equipment will be requested from you and then destroyed upon the return of the equipment.

**LEGISLATION - CONFIDENTIALITY**
In accordance with Articles L. 1121-1 et seq. of the French Public Health Code, the Committee on Human Research studied this research project and issued a favourable opinion on 01/04/2020.
An insurance policy, number 146 177 524, was taken out by the sponsor of the trial, the Côte d'Azur University - 20 avenue Valrose - BP 2135 - 06103 Nice Cedex 2, with the company MMA Entreprise, to cover the risks linked to this research.
Any information about you collected during this trial will be treated confidentially.
Only those responsible for the study and possibly the health authorities will have access to this data. With the exception of these people - who will treat the information in the strictest respect of medical secrecy - your anonymity will be preserved. The publication of the results of the study will not include any individual results.
The data recorded over the course of this study will be subject to computerised processing by the sponsor. As this is personal data, you have the right of access, rectification, portability, deletion or limitation in the processing of data concerning you at any time by contacting the
Data Protection Officer, Mr. Didier Martin at the Côte d'Azur University and those in charge of the study. As regards information of a medical nature, this right is exercised through the intermediary of Professor Nicolas Chevalier at the University Hospital of Nice, in accordance with France’s law on Information Technology, Data Files and Civil Liberties, No. 78-17 of 6 January 1978, amended by law No. 94-548 of the 1st of July 1994, and Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of individuals with regard to the processing of personal data and on the free movement of such data and repealing Directive 95/46/EC (General Data Protection Regulation). The project received a notification of compliance with reference to methodology, and an analysis of the impact on privacy delivered by the Data Protection Officer of the Côte d’Azur University on 28/04/2020.

In accordance with Article L. 1122-1, as amended, of the French Public Health Code (law of March 2002 on patients’ rights), the overall results of the study can be communicated to you if you wish.

If you have any questions during your participation in this study, you may contact the principal investigators of this study:

- Prof. Nicolas Chevalier, phone: 04.92.03.55.19 at the Archet 2 University Hospital of Nice
- Prof. Antonio Iannelli, phone: 04.92.03.55.19 at the Archet 2 University Hospital of Nice

Or the scientific head of research:

- Prof. Fabienne d’Arripe-Longueville, phone: 04.89.15.39.55 at the LAMHESS of the Côte d’Azur University.

Or the Data Protection Officer:

- Mr. Didier Martin, phone: 04.89.15.11.99 at the Côte d’Azur University

You are free to accept or refuse to participate in this study. This will in no way affect the quality or the level of care you will receive, which will be the same as it has been thus far. During the course of the study, you may also decide to discontinue your participation without having to justify your decision.

Thank you for taking the time to read this newsletter. If you agree to participate in this research study, we invite you to sign the attached consent form.
**Consent – Group C – V3 (04/03/2020)**

**ID No. – RCB: 2020-A00172-37**

---

**FORMULAIRE DE CONSENTEMENT**

**POUR LA PARTICIPATION A L’ETUDE OCAPAS**

**Etude Activité Physique et Chirurgie Bariatrique**

---

**Research title:** "OCAPAS" Scientific study

---

I the undersigned .......................................................... (Last name and first name of the volunteer), accept to participate in the "OCAPAS" study.

The objectives and terms of the study were clearly explained to me by Prof. Nicolas Chevalier and Prof. Antonio Iannelli.

I have read and understood the information sheet given to me.

I accept that the documents in my medical file that relate to the study may be accessible to those responsible for the study and possibly to the health authorities. With the exception of these persons, who will treat the information in the strictest respect of medical confidentiality, my anonymity will be preserved.

I accept that my personal data collected during this study may be subject to automated processing by the research organisers. I may exercise my right of access, rectification, portability, deletion or limitation of the processing of data concerning me by contacting the data protection representative Mr. Didier Martin at the Côte d'Azur University, and as regards information of a medical nature by contacting Professor Nicolas Chevalier at the Nice University Hospital.

I understand that my participation in the study is voluntary.

I am free to accept or refuse to participate, and I am free to stop my participation at any time during the course of the study. This will not affect the quality of care I will receive.

My consent does not relieve the organisers of this study of their responsibilities. I retain all my rights under the law.

Having discussed it and having obtained the answers to all my questions, I freely and voluntarily agree to participate in the research study proposed to me.

---

Prepared in Nice, on _ _ / _ _ / _ _ _ _

*Name and signature of the investigator*  
*Signature of the volunteer*

---

Page 1 sur 1
### SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Addressed on page number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>16</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>16</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>17</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>1; 17-18</td>
</tr>
<tr>
<td></td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>17-18</td>
</tr>
<tr>
<td></td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>15; 17-18</td>
</tr>
</tbody>
</table>
### Introduction

<table>
<thead>
<tr>
<th>Background and rationale</th>
<th>6a</th>
<th>Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention</th>
<th>4-6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6b</td>
<td>Explanation for choice of comparators</td>
<td>10-12</td>
</tr>
<tr>
<td>Objectives</td>
<td>7</td>
<td>Specific objectives or hypotheses</td>
<td>6-7</td>
</tr>
<tr>
<td>Trial design</td>
<td>8</td>
<td>Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)</td>
<td>7</td>
</tr>
</tbody>
</table>

### Methods: Participants, interventions, and outcomes

<table>
<thead>
<tr>
<th>Study setting</th>
<th>9</th>
<th>Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility criteria</td>
<td>10</td>
<td>Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)</td>
<td>7-8</td>
</tr>
<tr>
<td>Interventions</td>
<td>11a</td>
<td>Interventions for each group with sufficient detail to allow replication, including how and when they will be administered</td>
<td>13-14</td>
</tr>
<tr>
<td></td>
<td>11b</td>
<td>Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)</td>
<td>7-8</td>
</tr>
<tr>
<td></td>
<td>11c</td>
<td>Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)</td>
<td>13-14</td>
</tr>
<tr>
<td></td>
<td>11d</td>
<td>Relevant concomitant care and interventions that are permitted or prohibited during the trial</td>
<td>7-8</td>
</tr>
<tr>
<td>Outcomes</td>
<td>12</td>
<td>Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended</td>
<td>8-12</td>
</tr>
<tr>
<td>Participant timeline</td>
<td>13</td>
<td>Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)</td>
<td>7</td>
</tr>
<tr>
<td>Sample size</td>
<td>14</td>
<td>Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>----</td>
<td>------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Recruitment</td>
<td>15</td>
<td>Strategies for achieving adequate participant enrolment to reach target sample size</td>
<td></td>
</tr>
</tbody>
</table>

**Methods: Assignment of interventions (for controlled trials)**

**Allocation:**

<table>
<thead>
<tr>
<th>Sequence generation</th>
<th>16a</th>
<th>Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment mechanism</td>
<td>16b</td>
<td>Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned</td>
</tr>
<tr>
<td>Implementation</td>
<td>16c</td>
<td>Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions</td>
</tr>
<tr>
<td>Blinding (masking)</td>
<td>17a</td>
<td>Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how</td>
</tr>
<tr>
<td></td>
<td>17b</td>
<td>If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial</td>
</tr>
</tbody>
</table>

N/A, blinding cannot be strictly guaranteed in this study, only strategies to limit potential bias were taken.
### Methods: Data collection, management, and analysis

**Data collection methods**

<table>
<thead>
<tr>
<th>Plan</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>18a</td>
<td>Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (e.g., duplicate measurements, training of assessors) and a description of study instruments (e.g., questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol.</td>
</tr>
<tr>
<td>18b</td>
<td>Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols.</td>
</tr>
</tbody>
</table>

**Data management**

<table>
<thead>
<tr>
<th>Plan</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Plans for data entry, coding, security, and storage, including any related processes to promote data quality (e.g., double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol.</td>
</tr>
</tbody>
</table>

**Statistical methods**

<table>
<thead>
<tr>
<th>Plan</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20a</td>
<td>Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol.</td>
</tr>
<tr>
<td>20b</td>
<td>Methods for any additional analyses (e.g., subgroup and adjusted analyses).</td>
</tr>
<tr>
<td>20c</td>
<td>Definition of analysis population relating to protocol non-adherence (e.g., as randomised analysis), and any statistical methods to handle missing data (e.g., multiple imputation).</td>
</tr>
</tbody>
</table>

### Methods: Monitoring

**Data monitoring**

<table>
<thead>
<tr>
<th>Plan</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>21a</td>
<td>Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed.</td>
</tr>
<tr>
<td>21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial.</td>
</tr>
</tbody>
</table>

**Harms**

<table>
<thead>
<tr>
<th>Plan</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct.</td>
</tr>
</tbody>
</table>
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor 15

Ethics and dissemination

Research ethics approval 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 16

Protocol amendments 25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) 16

Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) 8, 17-18

Consent or assent 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable N/A, no ancillary studies are planned

Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial 15

Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial and each study site 17

Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators 16-18

Ancillary and post-trial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation N/A, no ancillary studies or post-trial care are planned

Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions 8, 16

Dissemination policy 31b Authorship eligibility guidelines and any intended use of professional writers 17-18
### Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code

**Appendices**

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>31c</td>
<td>Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code</td>
<td>16</td>
</tr>
<tr>
<td>Informed consent materials</td>
<td>Model consent form and other related documentation given to participants and authorized surrogates Translated consent forms are provided as a supplementary file.</td>
<td></td>
</tr>
<tr>
<td>Biological specimens</td>
<td>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable N/A no biological specimens were collected as part of this trial</td>
<td></td>
</tr>
</tbody>
</table>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license.*